Gossamer Bio, Inc. (NASDAQ:GOSS) Receives Average Recommendation of “Hold” from Brokerages

Shares of Gossamer Bio, Inc. (NASDAQ:GOSS) have earned an average rating of “Hold” from the nine analysts that are covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, three have issued a hold recommendation and four have given a buy recommendation to the company. The average 1 year target price among brokers that have covered the stock in the last year is $3.20.

Several analysts recently weighed in on GOSS shares. HC Wainwright restated a “buy” rating on shares of Gossamer Bio in a research note on Monday, July 27th. Weiss Ratings cut Gossamer Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, May 19th. Finally, Leerink Partners raised Gossamer Bio from a “market perform” rating to an “outperform” rating and set a $1.00 target price on the stock in a report on Tuesday, July 28th.

Hedge Funds Weigh In On Gossamer Bio

Several large investors have recently modified their holdings of GOSS. MMA Asset Management LLC purchased a new position in Gossamer Bio in the fourth quarter worth about $31,000. Soltis Investment Advisors LLC purchased a new stake in shares of Gossamer Bio during the fourth quarter valued at approximately $31,000. Beacon Pointe Advisors LLC purchased a new stake in shares of Gossamer Bio during the fourth quarter valued at approximately $34,000. Ieq Capital LLC bought a new stake in shares of Gossamer Bio during the fourth quarter valued at approximately $35,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Gossamer Bio during the fourth quarter valued at approximately $35,000. Hedge funds and other institutional investors own 81.23% of the company’s stock.

Gossamer Bio Price Performance

Shares of NASDAQ GOSS opened at $0.18 on Friday. Gossamer Bio has a 1 year low of $0.11 and a 1 year high of $3.87. The firm has a 50-day moving average of $0.17 and a 200 day moving average of $0.66. The stock has a market cap of $41.78 million, a P/E ratio of -0.23 and a beta of 2.04.

Gossamer Bio (NASDAQ:GOSS) last announced its quarterly earnings data on Friday, May 15th. The company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.03). The business had revenue of $16.95 million for the quarter, compared to analyst estimates of $4.67 million. Research analysts expect that Gossamer Bio will post -0.39 earnings per share for the current fiscal year.

About Gossamer Bio

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.